Albert Robichaud, Chief Scientific Officer at Sage Therapeutics, Inc. (SAGE), sold 54,100 shares at $163.93 ($8.6M) on 2017-12-14, disclosed to the SEC on 2017-12-14.
Open-market sale of $8.6M SAGE by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $158.18 | 16,748 | $2.6M | 30.7% |
| 2 | $159.46 | 8,734 | $1.4M | 16.1% |
| 3 | $160.12 | 21,410 | $3.4M | 39.7% |
| 4 | $161.40 | 6,187 | $999K | 11.6% |
| 5 | $163.93 | 1,021 | $167K | 1.9% |
| Total | $159.63 avg | 54,100 |
| $8.6M |
| 100% |
| Filing → |
| SAGE | SELL | 2017-12-14 | $9.6M | — | Filing → |
| SAGE | SELL | 2016-07-14 | $880K | — | Filing → |
| SAGE | SELL | 2016-01-26 | $1.6M | — | Filing → |